|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Overall, our study not only uncovers the regulatory effect of USP10 on the protein abundance of Smad4, but also indicates that USP10 could be regarded as a potential intervention target for the metastatic HCC in Smad4-positive patients.
|
31721429 |
2020 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
HEY2 acting as a co-repressor with smad3 and smad4 interferes with the response of TGF-beta in hepatocellular carcinoma.
|
31396342 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Pathway analysis suggested that putative target genes of these essential miRNAs were involved in HCC-associated signaling pathways, such as Wnt, TGF-β, and Ras; whereas protein-protein network (PPI) analysis demonstrated that some validated target genes of these miRNAs, such as PIK3CA, AKT1, MYC, JUN, SMAD4, and SRC, were hub target genes as they have more counts of interacting protein.
|
31293639 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In addition, low-expression of Six2 weakened TGF-β induced Smad4 activation and epithelial-mesenchymal transition in HCC cell lines.
|
31564506 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Mutations in EGFR, PTEN, RB1, TP53, and ERBB2 were found in CLC, whereas mutations in KIT, BRAF, PTEN, TP53, and SMAD4 were found in the coexistent HCC-like area.
|
31261448 |
2019 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
To confirm that miR-888 regulates SMAD4 expression in HCC, a dual-luciferase reporter assay was applied.
|
30915745 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In analysis of correlation with tumor stage, both protein and mRNA expression of TGFβ1, Smad1, Smad2 and Smad4 in patients with stage III HCC were significantly lower than those with stage IV HCC (P < 0.001), while the protein and mRNA expression of Smad3 in patients with IV stage HCC was significantly higher in comparison to those with stage IV HCC (P < 0.001).
|
29799303 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Disruption of ELF results in mislocalization of Smad3 and Smad4, leading to compromised TGF-β signaling. c-Myc is an important oncogenic transcription factor, and the disruption of TGF-β signaling promotes c-Myc-induced hepatocellular carcinoma (HCC) carcinogenesis.
|
29690860 |
2018 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Smad4 shows increase of the previous parameters in HCC compared to CHC cases. pSmad2/3 and Smad4 can be used as diagnostic and/or prognostic markers for progression of HCV-related fibrosis to cirrhosis and further progression to HCC.
|
29924446 |
2018 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the functional role of the cyclin D1-dependent activation of Smad2/3 and Smad4 in hepatocellular carcinoma (HCC) CSCs and in HCC primary tumors.
|
28415588 |
2017 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt.
|
28445968 |
2017 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Therefore, activation of miR-130a-3p or inactivation of Smad4 could be a novel approach for the treatment of HCC.
|
26817584 |
2016 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Nuclear SMAD4 levels were significantly increased in patient HCC tumors as compared with adjacent tissues.
|
25531314 |
2015 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that HBx can modulate NUPR1 expression through the Smad4 pathway and NUPR1 has a role in hepatocellular carcinoma progression.
|
26392315 |
2015 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
A noncanonical pathway links autophagy, miR-224, Smad4, and HBV-associated HCC.
|
23913306 |
2014 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Based on this finding, we further demonstrated that in hepatitis B virus (HBV)-related HCC, aberrant autophagy (low autophagic activity) results in accumulation of MIR224 and decreased expression of the target gene Smad4, which leads to increased cell migration and tumor formation.
|
25068270 |
2014 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The clinical relevance of our experimental observations was supported by a statistically significant inverse correlation between miR-224 and SMAD4 transcript expression in tumor versus paired adjacent non-tumorous tissues from HCC patients (p<0.001, r= -0.45, R(2) =0.122).
|
23922662 |
2013 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our study indicates that the induction of HCC cell proliferation is independent of the SMAD signaling pathway, as Smad4 knockdown of HCC cell lines still leads to the upregulation of CDK1 and cyclin B1 expression after BMP4 treatment.
|
22241220 |
2012 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
We investigated the role of Smad4 in TGF-beta1-induced cell proliferation and apoptosis of HCC cell line SMMC-7721.
|
18949401 |
2008 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
RGD |
The expressions of Smad4 and phosphorylated Smad2 in the HCC tissue was significantly lower than those in normal liver tissue.
|
18971187 |
2008 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Reduced ELF but not TBRII, or Smad4 was observed in 8 of 9 human HCCs (P<0.017).
|
17546056 |
2007 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Smad4 mRNA was detected in all HCCs; while, using immunohistology, loss of Smad4 expression was found in 10% of HCCs.
|
15455231 |
2004 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
To investigate this, 21 surgically resected HCCs were immunostained with antibodies to Smad4 and TGF-beta receptor II.
|
12378510 |
2002 |
|
Liver carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that mutations of the TGFbetaRII, Smad2, and Smad4 genes are rare, and that genetic instability is uncommon in human hepatocellular carcinoma.
|
9863018 |
1999 |
|
Liver carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Smad2 and Smad4 gene mutations in hepatocellular carcinoma.
|
10490821 |
1999 |